VolitionRx Takes Center Stage as Silver Sponsor at 44th ISICEM Congress in Brussels
VolitionRx Takes Center Stage as Silver Sponsor at 44th ISICEM Congress in Brussels
VolitionRx Limited (NYSE AMERICAN: VNRX), a leading multi-national epigenetics company, is excited to announce its participation as a silver sponsor at the 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM), happening in Brussels, Belgium from March 18 to 21, 2025. The event aims to elevate patient care in critical situations through innovative discussions and education.
At this congress, Volition will showcase multiple presentations centered on its groundbreaking Nu.Q® H3.1 epigenetic screening technology, specifically within the contexts of intensive care and emergency medicine. This event is particularly significant for the company, marking an important step towards addressing critical healthcare challenges, particularly in sepsis management.
Key Insights from the Conference
Dr. Andrew Retter, the Chief Medical Officer at Volition, expressed enthusiasm for the company's participation, stating, "Volition is thrilled to be a supporting presence at the ISICEM Congress. This year is exceptionally exciting as we unveil multiple groundbreaking studies validating the crucial role of NETosis, NETs, and specifically nucleosomes-H3.1 in screening and monitoring sepsis in Intensive Care Unit (ICU) settings."
He further elaborated, "These advancements not only emphasize our commitment to enhancing patient outcomes but also indicate our leadership position in a burgeoning market opportunity of over $1 billion aimed at sepsis care. The potential for improved patient monitoring with H3.1 nucleosomes as a new diagnostic tool is particularly promising."
The congress will feature several notable presentations that highlight the applications of Nu.Q® H3.1 technology:
- - Presentation 1: Circulating NETs levels by Professor Djillali Annane, March 18, at 2:30 PM in the Panoramic Room.
- - Presentation 2: Functional Endotyping in Sepsis by Professor Evangelos Giamarellos-Bourboulis, March 19, at 9:45 AM in the 100 Hall.
- - Presentation 3: Neutrophils in Host Response and Organ Dysfunction by Professor Michael Bauer, March 19, at 1:45 PM in the Arc room.
- - Presentation 4: The Time for Precision has Come by Professor Evangelos Giamarellos-Bourboulis, March 19, at 3:35 PM in the Arc room.
- - Presentation 5: H3.1 for Early Recognition of Sepsis by Professor Djillali Annane, March 20, at 10:00 AM in the 100 Hall.
- - Presentation 6: NETosis as an Important Predictor of Organ Dysfunction by Dr. Lieuwe Bos, March 20, at 11:00 AM in the 100 Hall.
Moreover, Dr. Andrew Retter will also serve as an invited speaker at the Praetorian Doctoral Network Satellite Symposium held on March 19 at 11:35 AM. He will discuss the impactful Nu.Q® test that measures circulating H3.1 nucleosome levels, which serve as a surrogate marker for neutrophil extracellular traps (NETs) in blood samples.
About the ISICEM Congress
The ISICEM Congress is renowned as one of the largest and most significant gatherings in the field of Intensive Care, attracting around 5,000 participants globally. The primary goal of ISICEM is to enhance the clinical management of critically ill patients by fostering ongoing education, training, and encouraging research development. With valuable firsthand knowledge shared, attendees can return to their respective units with actionable insights to improve practice and patient outcomes in intensive care settings.
About VolitionRx
VolitionRx is dedicated to advancing the science of epigenetics, focusing on innovative diagnostic tools that aid in the early detection and monitoring of diseases, including cancers and conditions linked to NETosis such as sepsis. Based in Belgium with additional research hubs in the U.S. and London, VolitionRx is committed to improving not only the life expectancy of patients but also their overall quality of life through promising advancements in medical diagnostics.
For any media inquiries, please contact:
- - Louise Batchelor at [email protected]
- - Investor Relations: Jeremy Feffer, LifeSci Advisors, [email protected]
Together, we look forward to a progressive discussion and advancement in the world of intensive care medicine at this prestigious congress!
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.